…World’s first large-scale clinical trials in psilocybin therapy for treatment-resistant depression
The trial will begin in the first quarter of 2018 and is planned to include clinical sites in Czech Republic, Finland, Germany, the Netherlands, Norway, Portugal, Spain and the UK.
COMPASS Pathways is a healthcare company, founded in 2015 to accelerate patient access to evidence-based innovation in mental health. We are developing psilocybin therapy through late-stage clinical trials in the EU and US for patients with treatment-resistant depression. We will improve mental health through the development of new patient care pathways, based on advances in neuroscience, psychotherapy, psychopharmacology, and technology … The selection of a CRO and development of clinical trial sites are the latest in a series of successful milestones for COMPASS, which completed pre-clinical trials and manufacturing to Good Manufacturing Practice (GMP) standards earlier this year. COMPASS was founded two years ago.
Original Article (Business Wire):
Compass Pathways Partners with worldwide clinical trials to conduct world’s first large-scale clinical trials in Psilocybin therapy for treatment-resistant depression
Artwork Fair Use: Cgoodwin
